Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Coinhibitory receptors are cell surface molecules expressed on activated T cells and other immune cells that transmit negative signals to dampen or terminate cellular activation. They are crucial for maintaining self-tolerance, preventing autoimmunity, and modulating responses to infections and cancer. Key members include PD-1, CTLA-4, LAG-3, TIGIT, and Tim-3. These receptors typically recruit intracellular phosphatases upon ligand binding, leading to reduced T cell activation. Therapeutic blockade of coinhibitory receptors has revolutionized cancer treatment but can also trigger immune-related adverse events.
Engagement of coinhibitory receptors recruits intracellular phosphatases via phosphorylated ITIMs, leading to dephosphorylation of key signaling molecules downstream of the TCR pathway, reducing cellular activation, proliferation, cytokine production, and effector function.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Coinhibitory Receptor (N/A).